Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service radiofrequency ablation (facet, genicular, basivertebral) cases in Alabama: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (252 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 57 | 4,483 | 45% |
| 2020 | 61 | 4,246 | 49% |
| 2021 | 59 | 4,330 | 54% |
| 2022 | 69 | 3,950 | 58% |
| 2023 | 64 | 4,221 | 62% |
| 2024 | 71 | 4,863 | 64% |
| 2025 from claims | – | 5,109 4,689–5,406 | 65% |
| 2026 forecast | – | 5,334 4,693–6,156 | 66% |
| 2027 forecast | – | 5,593 4,782–6,665 | 67% |
| 2028 forecast | – | 5,861 4,891–7,177 | 68% |
| 2029 forecast | – | 6,139 5,014–7,699 | 68% |
| 2030 forecast | – | 6,426 5,148–8,235 | 69% |
Facet, genicular, and basivertebral nerve ablation. Professional codes (what the surgeon bills): CPT 64635, 64633, 64624, 64625, 64628.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 38% of the cases CMS names in Alabama; 35 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 26% hospital outpatient, 9% surgery center, 65% office. The share outside the hospital has moved +7 pts since 2019, so more of this market is decided in surgery centers and offices each year.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Florida | 451 | 40,806+0.5%/yr | +0.5%/yr | 17.4 | 95% | 48,900 in 2030+3.1%/yr |
| Texas | 464 | 34,513−0.2%/yr | −0.2%/yr | 15.2 | 78% | 40,900 in 2030+2.9%/yr |
| Georgia | 191 | 13,392−3%/yr | −3%/yr | 14.7 | 91% | 15,000 in 2030+1.9%/yr |
| North Carolina | 172 | 11,392−0.4%/yr | −0.4%/yr | 10.9 | 82% | 12,200 in 2030+1.2%/yr |
| Virginia | 121 | 10,959+2.8%/yr | +2.8%/yr | 10.1 | 80% | 13,100 in 2030+3%/yr |
| Oklahoma | 78 | 8,975+3.6%/yr | +3.6%/yr | 17.8 | 65% | 11,900 in 2030+4.8%/yr |
| Louisiana | 95 | 8,745+0.5%/yr | +0.5%/yr | 20.3 | 63% | 10,700 in 2030+3.4%/yr |
| Maryland | 110 | 8,602−0.5%/yr | −0.5%/yr | 9.5 | 97% | 8,640 in 2030+0.1%/yr |
| Tennessee | 111 | 8,564+0.4%/yr | +0.4%/yr | 11.6 | 88% | 10,900 in 2030+4.2%/yr |
| South Carolina | 107 | 7,768−1.3%/yr | −1.3%/yr | 10.9 | 87% | 8,970 in 2030+2.4%/yr |
| Arkansas | 73 | 7,188−5.6%/yr | −5.6%/yr | 18.3 | 76% | 7,600 in 2030+0.9%/yr |
| Kentucky | 75 | 6,856−6.1%/yr | −6.1%/yr | 14.2 | 81% | 7,510 in 2030+1.5%/yr |
| Mississippi | 50 | 4,876+2%/yr | +2%/yr | 12.5 | 86% | 7,510 in 2030+7.5%/yr |
| West Virginia | 24 | 1,871−2.4%/yr | −2.4%/yr | 8.5 | 17% | 2,300 in 2030+3.5%/yr |
| Delaware | 24 | 1,803+8.7%/yr | +8.7%/yr | 10.2 | 100% | 3,040 in 2030+9.1%/yr |
| District of Columbia | 9 | 229−7.4%/yr | −7.4%/yr | 3.5 | 96% | 240 in 2030+0.9%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Peripheral nerve stimulation & intrathecal pumps | 6 | 319+4.8%/yr | +4.8%/yr | 0.70.5× | 49% | 670 in 2030+13%/yr |
| Spinal cord & DRG stimulation | 4 | 201−12%/yr | −12%/yr | 0.40.4× | 35% | 180 in 2030−1.6%/yr |
Radiofrequency ablation (facet, genicular, basivertebral) in every state, and its device makers · Every procedure market in Alabama · Every state · Compare with Florida
Boston Scientific leads with 71% of company spending on these surgeons in 2025, +23 pts on 2024.
In 2025, 6 companies reported engagement with Alabama’s surgeons worth $30K in consulting, speaking, meals and travel tied to these products, about $424 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 2 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.